Lexeo Therapeutics, Inc. Common Stock
LXEO
NASDAQ·Healthcare·Biotechnology·Mkt cap $384.0M
$4.89
▲ +1.03%
P/E
-5.96
Mkt Cap
$384.0M
52-Wk Range
$3.99–$10.99
52-Week Range
$3.99 - $10.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 6.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary AAVrh10 vector technology with improved cardiac and CNS tropism
- Focused pipeline targeting genetically-defined patient populations with high unmet medical needs
- Experienced management team with deep expertise in gene therapy development and commercialization
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Clinical trial progression and potential regulatory approvals for lead candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+16.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LXEO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 12, 2026
Reported EPS of -$0.30 vs -$0.29 consensus (-5.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Chardan Capital · May 11, 2026
vs Industry
How LXEO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related